Congress to be Held in São José do Rio Preto from November 25-27
SUMMIT, N.J., November 25, 2014 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced that the company will hold a High Quality Tilapia Congress in São José do Rio Preto in Brazil, on November 25-27. The Congress will be attended by nearly 75 key opinion leaders and customers in the Latin American tilapia industry.
“Production and consumption of tilapia continues to grow at a fast pace,” said Rodrigo Zanolo, aquaculture marketing manager, Merck Animal Health. “We are pleased to offer services and programs such as the High Quality Tilapia Congress, which help support producers as they meet growing global demand for safe and sustainable fish protein.”
The Congress will consist of three principal sessions: “Industry & Environment” and “Production” on November 26, followed by “Market” on November 27. Sessions will focus on timely topics related to tilapia production including the impact of climate change, the strategic importance of organized associations of fish farmers, good management practices, and the specifications and requirements that retailers are driving towards. Presentations from academic experts, industry leaders and Merck Animal Health representatives will be featured, including:
Session 1 – Industry & Environment – November 26
- Rui Nobrega – Business Unit Director, Aquaculture and Swine, Merck Animal Health
- Fábio Betti Rodrigues Salgado – Partner, Corall
- Dr. Wilson Flavio Feltrim Roseghini – Assistant Professor, Federal University of Paraná; Financial Director, Brazilian Climatology Association; Editor, Revista Brasileira de Climatologia (Brazilian Climatology Magazine)
- Felipe Sandoval Precht – President of SalmonChile, the Chile Salmon Industry Association
Session 2 – Production – November 26
- Luis Caro Lagos – General Manager, ORZA
- Felipe Manterola Gana – General Manager, SalmonChile, the Chile Salmon Industry Association
- Rodrigo Zanolo – Aquaculture Marketing Manager, Merck Animal Health
- Dr. Fernando Kubitza – Consultant, Acqua Imagem
Session 3 – Market – November 27
- Adriano Romero – Founder, Agroinova
- Oscar Parra Ponce – Business Unit Manager Aqua Latin America, Merck Animal Health
- Meg Caetano Fellipe – Manager, Grupo Pão de Açúcar (GPA)
For more information about Merck Animal Health’s aquaculture business, visit http://aqua.merck-animal-health.com.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).